Konstantin Glebov
Research Subjects
Konstantin Glebov has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- A.N. Severtsev
Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, 117513, Moscow, Russian Federation
1 shared publication - Antonio Marcilla
Department of Pharmacy and Pharmaceutical Technology and Parasitology Faculty of Pharmacy and Food Sciences Universitat de València Valencia Spain
1 shared publication - Benedetta Bussolati
Department of Medical Sciences, University of Turin, Turin, Italy
1 shared publication - Carlos Salomon
Translational Extracellular Vesicles in Obstetrics and Gynae‐Oncology Group Frazer Institute Faculty of Health, Medicine and Behavioural Sciences The University of Queensland Herston Queensland Australia
1 shared publication Christian Neri
Sorbonne Université, CNRS Inserm, Institut de Biologie Paris Seine (IBPS) Center for Neuroscience at Sorbonne Université (NeuroSU) Paris France
1 shared publication- G.I. Kryuchkov
City Clinical Hospital No. 15 named after O.M. Filatov, 111539, Moscow, Russian Federation
1 shared publication
Latest Publications
- Open Access
The quality–failure paradox in extracellular vesicle therapeutics: quantitative benchmarking of 152 clinical trials against CAR-T cell therapies
The stall in clinical translation of extracellular vesicle (EV) therapeutics requires addressing critical and hidden causes of attrition and delays. Despite more than 150 registered clinical trials and fifteen years of clinical investigation, small EV (sEV) therapeutics have yielded zero FDA approvals—a translational deficit that has received remarkably little quantitative scrutiny. We systematically evaluated 783 EV-related clinical trials (152 of which therapeutic) registered through December 2025, benchmarking the sEV pipeline against 1,131 CAR-T cell therapy trials (ex-China) that share the “process is the product” manufacturing constraint, yet have delivered six FDA-approved products. A quality–failure paradox emerges, in which industry-sponsored sEV trials exhibit 39% higher composite methodological quality (quality index 2.49 vs. 1.79) yet fail at approximately five-fold the rate of academic programmes (28.6% vs. 5.1%; OR=7.40, 95% CI 2.5–22.3, p=0.0004). Cross-modality replication in CAR-T trials confirms the direction of this association (OR=2.51, p<0.001; Cochran– Mantel–Haenszel pooled OR=2.76, p<0.001). Registry abandonment—affecting 24% of academic sEV trials—constitutes a hidden failure mode that, when reclassified, dissolves the apparent paradox. Premature clinical entry of incompletely defined products, rather than insufficient methodological rigour, represents the central constraint on sEV translational progress. The opacity of research data, inadequate pre clinical evaluation, and failure to report negative (null) findings in clinical trials create a hidden crisis that drains hundreds of millions invested by public and private sector—eroding the return on investment—and traps progress in cycles of duplicated effort, wasteful resource allocation, and missed learning opportunities.
Open AccessThe quality–failure paradox in extracellular vesicle therapeutics: quantitative benchmarking of 152 clinical trials against CAR-T cell therapies
The stall in clinical translation of extracellular vesicle (EV) therapeutics requires addressing critical and hidden causes of attrition and delays. Despite more than 150 registered clinical trials and fifteen years of clinical investigation, small EV (sEV) therapeutics have yielded zero FDA approvals—a translational deficit that has received remarkably little quantitative scrutiny. We systematically evaluated 783 EV-related clinical trials (152 of which therapeutic) registered through December 2025, benchmarking the sEV pipeline against 1,131 CAR-T cell therapy trials (ex-China) that share the “process is the product” manufacturing constraint, yet have delivered six FDA-approved products. A quality–failure paradox emerges, in which industry-sponsored sEV trials exhibit 39% higher composite methodological quality (quality index 2.49 vs. 1.79) yet fail at approximately five-fold the rate of academic programmes (28.6% vs. 5.1%; OR=7.40, 95% CI 2.5–22.3, p=0.0004). Cross-modality replication in CAR-T trials confirms the direction of this association (OR=2.51, p<0.001; Cochran– Mantel–Haenszel pooled OR=2.76, p<0.001). Registry abandonment—affecting 24% of academic sEV trials—constitutes a hidden failure mode that, when reclassified, dissolves the apparent paradox. Premature clinical entry of incompletely defined products, rather than insufficient methodological rigour, represents the central constraint on sEV translational progress. The opacity of research data, inadequate pre clinical evaluation, and failure to report negative (null) findings in clinical trials create a hidden crisis that drains hundreds of millions invested by public and private sector—eroding the return on investment—and traps progress in cycles of duplicated effort, wasteful resource allocation, and missed learning opportunities.
- Open Access
- 30 January 2026
- Published by Wiley in Journal of Extracellular Biology
- Vol. 5 (2)
‘Exosomes’: The Hype, the Chasm, and Beyond
- 30 January 2026
- Published by Wiley in Journal of Extracellular Biology
- Vol. 5 (2)
Open Access‘Exosomes’: The Hype, the Chasm, and Beyond
- 14 January 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (4) , 102061
MechA versus MoA in MSC-sEV therapeutics: bridging realities and expectations
- 14 January 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (4) , 102061
MechA versus MoA in MSC-sEV therapeutics: bridging realities and expectations
- Open Access
- 14 January 2026
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (1) , e70220
From Lab to Industry: Advancing the Translational Potential of Extracellular Vesicles Through the ISEV Translation, Regulation and Advocacy Committee (ISEV‐TRA)
Extracellular vesicles (EVs) have emerged as powerful mediators of intercellular communication with significant potential across biomedical, veterinary, cosmetic, agricultural and environmental applications. However, the translation of EV‐based discoveries into practical and commercially viable products remains constrained by scientific complexity, regulatory uncertainty and manufacturing challenges. To address these barriers, the International Society for Extracellular Vesicles (ISEV) established the Translation, Regulation and Advocacy Committee (ISEV‐TRA). ISEV‐TRA aims to catalyse the responsible advancement of EV technologies by fostering cross‐sector collaboration, harmonising quality and regulatory frameworks and providing strategic advocacy to enhance market readiness. Through targeted initiatives—such as workshops and the development of translational resources and guidance—ISEV‐TRA seeks to bridge the gap between research and real‐world implementation. By promoting dialogue amongst academia, industry, investors and policymakers, ISEV‐TRA positions itself as a central driver in shaping the global roadmap for EV translation and commercialisation.
- 14 January 2026
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (1) , e70220
Open AccessFrom Lab to Industry: Advancing the Translational Potential of Extracellular Vesicles Through the ISEV Translation, Regulation and Advocacy Committee (ISEV‐TRA)
Extracellular vesicles (EVs) have emerged as powerful mediators of intercellular communication with significant potential across biomedical, veterinary, cosmetic, agricultural and environmental applications. However, the translation of EV‐based discoveries into practical and commercially viable products remains constrained by scientific complexity, regulatory uncertainty and manufacturing challenges. To address these barriers, the International Society for Extracellular Vesicles (ISEV) established the Translation, Regulation and Advocacy Committee (ISEV‐TRA). ISEV‐TRA aims to catalyse the responsible advancement of EV technologies by fostering cross‐sector collaboration, harmonising quality and regulatory frameworks and providing strategic advocacy to enhance market readiness. Through targeted initiatives—such as workshops and the development of translational resources and guidance—ISEV‐TRA seeks to bridge the gap between research and real‐world implementation. By promoting dialogue amongst academia, industry, investors and policymakers, ISEV‐TRA positions itself as a central driver in shaping the global roadmap for EV translation and commercialisation.
- 1 January 2025
- Published by Geotar-Media Publishing Group in Angiology and vascular surgery
- Vol. 31 (3) , 154-159
TIPS dysfunction: what has to be done?
Дисфункция шунта после трансъюгулярного внутрипеченочного портосистемного шунтирования: что делать?
- 1 January 2025
- Published by Geotar-Media Publishing Group in Angiology and vascular surgery
- Vol. 31 (3) , 154-159
TIPS dysfunction: what has to be done?
Дисфункция шунта после трансъюгулярного внутрипеченочного портосистемного шунтирования: что делать?
- 23 October 2017
- Published by Wiley in Journal of Neurochemistry
- Vol. 143 (4) , 445-454
γ‐Secretase in microglia – implications for neurodegeneration and neuroinflammation
γ‐Secretase is an intramembrane cleaving protease involved in the generation of the Alzheimer's disease (AD)‐associated amyloid β peptide (Aβ). γ‐Secretase is ubiquitously expressed in different organs, and also in different cell types of the human brain. Besides the involvement in the proteolytic generation of Aβ from the amyloid precursor protein, γ‐secretase cleaves many additional protein substrates, suggesting pleiotropic functions under physiological and pathophysiological conditions. Microglia exert important functions during brain development and homeostasis in adulthood, and accumulating evidence indicates that microglia and neuroinflammatory processes contribute to the pathogenesis of neurodegenerative diseases. Recent studies demonstrate functional implications of γ‐secretase in microglia, suggesting that alterations in γ‐secretase activity could contribute to AD pathogenesis by modulation of microglia and related neuroinflammatory processes during neurodegeneration. In this review, we discuss the involvement of γ‐secretase in the regulation of microglial functions, and the potential relevance of these processes under physiological and pathophysiological conditions. image This article is part of the series “Beyond Amyloid”.
- 23 October 2017
- Published by Wiley in Journal of Neurochemistry
- Vol. 143 (4) , 445-454
γ‐Secretase in microglia – implications for neurodegeneration and neuroinflammation
γ‐Secretase is an intramembrane cleaving protease involved in the generation of the Alzheimer's disease (AD)‐associated amyloid β peptide (Aβ). γ‐Secretase is ubiquitously expressed in different organs, and also in different cell types of the human brain. Besides the involvement in the proteolytic generation of Aβ from the amyloid precursor protein, γ‐secretase cleaves many additional protein substrates, suggesting pleiotropic functions under physiological and pathophysiological conditions. Microglia exert important functions during brain development and homeostasis in adulthood, and accumulating evidence indicates that microglia and neuroinflammatory processes contribute to the pathogenesis of neurodegenerative diseases. Recent studies demonstrate functional implications of γ‐secretase in microglia, suggesting that alterations in γ‐secretase activity could contribute to AD pathogenesis by modulation of microglia and related neuroinflammatory processes during neurodegeneration. In this review, we discuss the involvement of γ‐secretase in the regulation of microglial functions, and the potential relevance of these processes under physiological and pathophysiological conditions. image This article is part of the series “Beyond Amyloid”.